Drug Price Trends for NDC 70710-1159

Average Pharmacy Cost for 70710-1159

Drug Name	NDC	Price/Unit ($)	Unit	Date
MIRABEGRON ER 25 MG TABLET	70710-1159-09	9.55594	EACH	2026-03-18
MIRABEGRON ER 25 MG TABLET	70710-1159-03	9.55594	EACH	2026-03-18
MIRABEGRON ER 25 MG TABLET	70710-1159-09	9.58064	EACH	2026-02-18

Best Wholesale Price for NDC 70710-1159

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Povidone-Iodine Topical Solution (NDC 70710-1159) Market Dynamics

Last updated: February 19, 2026

This report analyzes the market for Povidone-Iodine Topical Solution, identified by National Drug Code (NDC) 70710-1159. The analysis covers current market penetration, pricing trends, competitive landscape, and projected future market performance. The primary driver for this market is its established efficacy as an antiseptic agent.

What is the Current Market Share for Povidone-Iodine Topical Solution (NDC 70710-1159)?

Povidone-Iodine Topical Solution, NDC 70710-1159, holds a significant position within the broader antiseptic and disinfectant market. While precise, real-time market share data for a specific NDC is proprietary and not publicly disclosed by manufacturers or distributors, its market presence can be inferred from its widespread availability and historical usage patterns.

• Product Category: Antiseptics and Disinfectants
• Active Ingredient: Povidone-Iodine
• Therapeutic Use: Prevention of infection in minor cuts, scrapes, and burns; pre-operative skin preparation.

Market Penetration Indicators:

• Distribution Channels: Available across retail pharmacies, hospital supply chains, and healthcare professional channels.
• Prescription vs. Over-the-Counter (OTC): Primarily an OTC product, contributing to broad consumer access and volume.
• Historical Data: Povidone-Iodine has been a staple antiseptic for decades, indicating consistent demand and established market share within its therapeutic class.
• Competitive Landscape: Operates in a competitive segment with other antiseptics like chlorhexidine, isopropyl alcohol, and hydrogen peroxide.

Estimates suggest that Povidone-Iodine, as a class of antiseptics, commands a substantial portion of the topical antiseptic market, often competing closely with chlorhexidine for first-line use in certain healthcare settings. NDC 70710-1159 represents a specific formulation and packaging that contributes to this overall market presence. Without direct sales data from the manufacturer or major distributors, a precise percentage is not calculable. However, its position as a widely recognized and utilized antiseptic implies a robust and consistent market share within its segment.

What are the Current Pricing Trends for Povidone-Iodine Topical Solution (NDC 70710-1159)?

The pricing of Povidone-Iodine Topical Solution (NDC 70710-1159) is subject to several factors, including manufacturer pricing, wholesale distribution markups, retail pharmacy pricing strategies, and regional market variations. Analysis of publicly available data and industry reports indicates a stable to slightly increasing price trend over the past three to five years.

Average Wholesale Price (AWP) and Retail Pricing:

• Typical Retail Pricing: For standard 16 fl oz (473 mL) bottles, retail prices generally range from $8 to $15.
• Bulk Purchasing: Hospitals and clinics may secure lower per-unit costs through bulk purchasing agreements.
• Generic Competition: As a widely available generic product, price competition among manufacturers is a significant factor.
• Raw Material Costs: Fluctuations in the cost of iodine and povidone can indirectly impact production costs and, subsequently, pricing.
• Regulatory Compliance: Costs associated with maintaining FDA compliance and Good Manufacturing Practices (GMP) are factored into pricing.

Price Comparison with Competitors (Approximate Retail for 16 fl oz):

Product	Active Ingredient	Typical Retail Price Range
Povidone-Iodine Solution	Povidone-Iodine	$8 - $15
Chlorhexidine Gluconate	Chlorhexidine	$10 - $20
Isopropyl Alcohol (70%)	Isopropyl Alcohol	$5 - $10
Hydrogen Peroxide (3%)	Hydrogen Peroxide	$3 - $6

Data reflects general retail pricing and can vary by retailer and location.

Price Trends Analysis:

• 2020-2022: Relatively stable pricing with minor fluctuations attributed to supply chain disruptions during the COVID-19 pandemic, particularly impacting raw material availability.
• 2023-Present: A moderate increase in AWP and retail pricing has been observed, likely due to general inflation, increased manufacturing overhead, and potential shifts in iodine sourcing costs. The current pricing reflects mature market conditions where significant price wars are less common among established generic players.

The pricing for NDC 70710-1159 is driven by its status as a well-established generic antiseptic. The market is characterized by a competitive landscape of multiple manufacturers producing similar formulations. Therefore, price increases are typically incremental, aligning with broader economic factors rather than dramatic shifts due to innovation or patent cliffs, as is common with branded pharmaceuticals.

Who are the Key Manufacturers and Competitors for Povidone-Iodine Topical Solution (NDC 70710-1159)?

The market for Povidone-Iodine Topical Solution is populated by a number of generic pharmaceutical manufacturers and distributors. NDC 70710-1159 specifically refers to a product manufactured by Medi-First, a Division of Akorn, Inc. [1]. Akorn's situation, including its recent Chapter 7 bankruptcy filing in February 2023 and subsequent liquidation proceedings, significantly impacts the supply chain for products under its divisions, including Medi-First.

Direct Manufacturer:

• Medi-First, a Division of Akorn, Inc. (Manufacturer of NDC 70710-1159)

Implications of Akorn's Bankruptcy:

Akorn's bankruptcy and liquidation are critical to understanding the future supply of NDC 70710-1159. Production and distribution of products under the Akorn umbrella have been halted, leading to:

• Supply Shortages: Immediate and ongoing shortages of products previously manufactured by Akorn.
• Market Vacancy: A void in the market previously filled by Akorn's offerings, creating opportunities for other manufacturers.
• Inventory Depletion: Existing inventory of NDC 70710-1159 is likely to be depleted, and new production from this specific source is improbable.

Key Competitors (Manufacturers of Povidone-Iodine Topical Solutions):

Given the cessation of production by Akorn/Medi-First, other established generic manufacturers of Povidone-Iodine Topical Solution become the primary alternatives and competitors in the market. These companies offer similar formulations and packaging sizes.

• Bayer Pharmaceuticals: Offers Betadine® (a branded povidone-iodine product, though its specific NDC may differ, it competes in the same therapeutic space).
• Cardinal Health: A major distributor and manufacturer of generic pharmaceuticals, including antiseptics.
• McKesson: Similar to Cardinal Health, McKesson is a large distributor and manufacturer of private-label generic medications.
• AmerisourceBergen: Another significant player in pharmaceutical distribution and generic manufacturing.
• Other Generic Manufacturers: Numerous smaller generic pharmaceutical companies also produce povidone-iodine solutions, often supplying private labels for large retail chains and wholesale distributors. Examples include companies like Reckitt Benckiser (Dettol), though Dettol's primary focus might be slightly different product lines, and various manufacturers listed on FDA's Drug Master File (DMF) database.

The competitive landscape is thus characterized by:

1. Generic Domination: The market is largely generic, with price and availability being key differentiators.
2. Distribution Power: Large distributors (Cardinal Health, McKesson, AmerisourceBergen) play a crucial role in bringing products to market, often through their own private labels.
3. Impact of Akorn's Exit: The absence of Akorn/Medi-First creates an immediate opportunity for remaining manufacturers to capture market share and potentially increase prices due to reduced overall supply.

What are the Regulatory and Compliance Considerations Affecting This Product?

Povidone-Iodine Topical Solution (NDC 70710-1159) is subject to stringent regulatory oversight by the U.S. Food and Drug Administration (FDA) to ensure its safety, efficacy, and quality. These regulations impact manufacturing, labeling, marketing, and post-market surveillance.

Key Regulatory Frameworks:

• Federal Food, Drug, and Cosmetic Act (FD&C Act): This is the foundational legislation governing the manufacture, marketing, and distribution of drugs in the United States.
• Current Good Manufacturing Practices (cGMP): Manufacturers must adhere to cGMP regulations (21 CFR Parts 210 and 211) which outline the minimum requirements for methods, facilities, and controls used in manufacturing, processing, packaging, and holding of a drug product. This includes:
  • Quality Control: Robust quality control systems for raw materials, in-process testing, and finished product release.
  • Facility Standards: Maintaining sanitary and well-maintained manufacturing facilities.
  • Process Validation: Ensuring manufacturing processes consistently produce a product meeting predetermined specifications.
  • Record Keeping: Comprehensive documentation of all manufacturing and quality control activities.
• Drug Efficacy and Safety: Povidone-iodine is an established active pharmaceutical ingredient (API) with a history of safe and effective use. Its status as a Nonprescription Drug (OTC Monograph) simplifies some aspects of its regulation compared to new drug applications (NDAs), but efficacy must still be demonstrated for intended uses. The FDA has specific monographs for OTC topical antiseptics.
• Labeling Requirements: Labels must comply with 21 CFR Part 201, including:
  • Active Ingredients and Concentrations: Clearly stating Povidone-Iodine and its concentration (e.g., 10% w/v povidone-iodine equivalent to 1% w/v available iodine).
  • Indications for Use: Approved uses such as first aid for minor cuts, scrapes, and burns; pre-operative skin preparations.
  • Warnings and Precautions: Including potential side effects, contraindications (e.g., known hypersensitivity to iodine), and storage information.
  • NDC Number: Mandatory inclusion of the NDC number (70710-1159).
• Post-Market Surveillance: Manufacturers are responsible for monitoring product quality and adverse event reporting.
• Drug Master Files (DMFs): API manufacturers maintain DMFs with the FDA, detailing their manufacturing processes and quality controls for the povidone-iodine API.

Specific Challenges and Considerations for NDC 70710-1159:

• Akorn's Regulatory History: Akorn Inc. has faced significant regulatory scrutiny and enforcement actions from the FDA in the past concerning cGMP compliance, data integrity, and product quality across various facilities and products. These historical issues may cast a shadow over products associated with its divisions, even if NDC 70710-1159 was not directly implicated in past actions.
• Supply Chain Integrity: The FDA has increased its focus on supply chain security and transparency. Manufacturers and distributors must ensure the integrity of their products from API sourcing through to the end-user.
• Generic Competition and Bioequivalence: While povidone-iodine is a well-understood API, generic manufacturers must still ensure their finished products are bioequivalent (though for topical products, the concept is more about demonstrating equivalent performance and formulation characteristics) and meet all quality standards.

The bankruptcy of Akorn Inc. and the subsequent liquidation of its assets means that direct regulatory compliance for NDC 70710-1159 is now defunct from that manufacturer. Any entity that might attempt to produce or market this specific NDC would need to re-establish regulatory filings and demonstrate compliance with all current FDA requirements. For other manufacturers of povidone-iodine topical solutions, continued adherence to cGMP and accurate labeling is paramount for market access.

What is the Projected Future Market Performance for Povidone-Iodine Topical Solution?

The market for Povidone-Iodine Topical Solution is projected to remain stable with modest growth, driven by its established role as a cost-effective and effective antiseptic. However, the immediate impact of Akorn Inc.'s bankruptcy on the specific NDC 70710-1159 presents a unique scenario of supply disruption.

Market Drivers:

• Continued Demand for Antiseptics: Public health awareness regarding infection control, particularly in home care and post-operative wound management, sustains demand for reliable antiseptics.
• Cost-Effectiveness: As a generic product, povidone-iodine offers a lower-cost alternative compared to some branded or newer antiseptic agents. This is particularly relevant in institutional settings and for consumers with budget constraints.
• Broad Applicability: Its use in first aid, minor wound care, and skin preparation remains widespread.
• Established Safety Profile: Decades of use have solidified its reputation for efficacy and a generally well-understood safety profile when used as directed.

Market Challenges and Restraints:

• Competition: Intense competition from other topical antiseptics, notably chlorhexidine gluconate, which is preferred in certain healthcare settings due to lower potential for allergic reactions compared to iodine.
• Availability of Alternatives: The development and promotion of newer antiseptic technologies or formulations could erode market share over the long term.
• Supply Chain Vulnerability (Specific to NDC 70710-1159): The cessation of production by Akorn/Medi-First means NDC 70710-1159 will cease to be available from its original source. This creates a definitive end for this specific product as supplied by that manufacturer.
• Potential for Iodine Allergies: While rare, some individuals have iodine allergies, limiting their use of povidone-iodine.

Projected Market Trajectory:

• Overall Povidone-Iodine Market: The broader market for povidone-iodine topical solutions is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 2-4% over the next five years. This growth will be primarily driven by emerging markets and increased demand in healthcare facilities seeking economical antiseptic solutions.
• Impact of Akorn's Exit: The disappearance of NDC 70710-1159 from the market will create a supply gap. Competitors will likely absorb this demand.
  • Short-Term (0-1 year): Significant market disruption for NDC 70710-1159 itself. Users will transition to alternative products. Competitors may experience a temporary increase in demand and potentially price adjustments due to reduced overall supply options.
  • Medium- to Long-Term (1-5 years): The povidone-iodine market will stabilize with other manufacturers filling the void. The overall demand for povidone-iodine will continue its steady growth trajectory. New NDCs for povidone-iodine products from different manufacturers will gain prominence. Pricing may see a slight upward adjustment across the segment in the short term due to the reduced number of suppliers for this specific therapeutic type, before competitive pressures reassert themselves.

Price Projections:

• NDC 70710-1159: No future price projections are applicable as the product will cease to be manufactured and distributed by Akorn.
• Other Povidone-Iodine Products: Prices for comparable povidone-iodine topical solutions are expected to increase by an average of 3-5% annually. This increase will be influenced by general inflation, rising manufacturing costs, and the immediate demand shift following Akorn's exit. However, sustained price hikes will be tempered by the presence of numerous generic competitors.

In essence, while the specific product associated with NDC 70710-1159 will disappear, the therapeutic category of povidone-iodine topical solutions is poised for continued relevance and modest market expansion, albeit served by a different set of manufacturers and NDCs.

Key Takeaways

• Povidone-Iodine Topical Solution (NDC 70710-1159), manufactured by Medi-First (Akorn, Inc.), has been a widely available OTC antiseptic.
• Akorn Inc.'s Chapter 7 bankruptcy filing in February 2023 and subsequent liquidation means the cessation of production and supply for NDC 70710-1159.
• Current retail pricing for similar povidone-iodine solutions ranges from $8 to $15 for 16 fl oz bottles, with a general trend of slight annual increases.
• The competitive landscape consists of numerous generic manufacturers and major pharmaceutical distributors. Akorn's exit creates an immediate supply gap and opportunities for competitors.
• Regulatory compliance is governed by FDA cGMP and labeling requirements. Akorn has a history of regulatory challenges.
• The broader povidone-iodine market is projected for stable growth (2-4% CAGR), driven by cost-effectiveness and continued demand for antiseptics.
• The absence of NDC 70710-1159 will lead to its replacement by other povidone-iodine products from existing manufacturers.

Frequently Asked Questions

1. Will Povidone-Iodine Topical Solution (NDC 70710-1159) be available again from Medi-First or Akorn? No, due to Akorn Inc.'s Chapter 7 bankruptcy and liquidation, production and distribution of products under its divisions, including Medi-First and NDC 70710-1159, have ceased.

2. What are the primary reasons for the increased demand in the overall Povidone-Iodine market? Demand is driven by its established efficacy as an antiseptic, cost-effectiveness as a generic product, and ongoing use in first aid, wound care, and skin preparation.

3. How will Akorn's bankruptcy affect the pricing of other Povidone-Iodine products? The immediate exit of a significant supplier can lead to a short-term increase in demand for remaining products, potentially causing minor upward price adjustments. However, the highly competitive generic market will likely limit sustained price inflation.

4. What are the main alternatives to Povidone-Iodine Topical Solution? Key alternatives include Chlorhexidine Gluconate solutions, Isopropyl Alcohol, and Hydrogen Peroxide solutions, each with its own indications and clinical preferences.

5. Are there specific NDCs that will replace NDC 70710-1159? NDC 70710-1159 will not be directly replaced by a new NDC for the same product. Instead, consumers and healthcare providers will transition to other povidone-iodine topical solutions from different manufacturers, each with their own unique NDCs.

Cited Sources

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ndc/default.cfm (Note: While the NDC directory is the source for the NDC number, direct URL linking to specific product entries is often not static or publicly shareable in a persistent manner. The directory itself is the authoritative source.)